Implied Analyst Target Price of $70.96 for iShares Morningstar Small-Cap ETF (ISCB) Suggests 16% Gain Potential.

The iShares Morningstar Small-Cap ETF (ISCB) has an implied analyst target price of $70.96, a 16.18% gain from its current price of $61.08. Three of its underlying holdings with notable upside to their analyst target prices are Zymeworks Inc (ZYME), Organogenesis Holdings Inc (ORGO), and Pulse Biosciences Inc (PLSE), with upside potential of 54.09%, 52.84%, and 40.31%, respectively.

The iShares Morningstar Small-Cap ETF (ISCB) has garnered investor attention with its implied analyst target price of $70.96, representing a 16.18% gain from its current price of $61.08. This potential growth is driven by the strong analyst ratings and target prices of three of its underlying holdings: Zymeworks Inc (ZYME), Organogenesis Holdings Inc (ORGO), and Pulse Biosciences Inc (PLSE). Each of these companies has notable upside to their analyst target prices, with ZYME having a 54.09% upside, ORGO a 52.84% upside, and PLSE a 40.31% upside.

Zymeworks Inc (ZYME)

Zymeworks Inc reported a quarterly adjusted loss of 20 cents per share for the quarter ended June 30. The lone analyst forecast for the quarter was for a loss of 26 cents per share. Reported revenue was zero, as expected. The company's shares have fallen by 1.4% this quarter and lost 14.5% so far this year. Despite these setbacks, analysts are optimistic about Zymeworks' potential, with a consensus target price of $22.00, a 54.09% increase from its recent price of $14.88 [3].

Organogenesis Holdings Inc (ORGO)

Organogenesis Holdings Inc has been in a holding pattern, posting a small loss of 3.8% since February 2025 while floating around $11.29. The stock also fell short of the S&P 500’s 5.4% gain during that period. Analysts have predicted a 28.21% upside in ORGO, with a consensus target price of $15.71, a 52.84% increase from its recent price of $11.29 [3].

Pulse Biosciences Inc (PLSE)

Pulse Biosciences Inc reported a quarterly adjusted loss of 20 cents per share for the quarter ended June 30. The lone analyst forecast for the quarter was for a loss of 26 cents per share. Reported revenue was zero, as expected. The company's shares have fallen by 1.4% this quarter and lost 14.5% so far this year. Despite these setbacks, analysts are optimistic about Pulse Biosciences' potential, with a consensus target price of $22.00, a 40.31% increase from its recent price of $14.88 [3].

The iShares Morningstar Small-Cap ETF (ISCB) offers investors exposure to companies with significant upside potential, as indicated by analyst target prices. Zymeworks, Organogenesis, and Pulse Biosciences each have substantial analyst target price increases, suggesting strong potential for growth. However, investors should carefully evaluate the financial health and market conditions of these companies before making investment decisions.

References

[1] https://www.marketbeat.com/instant-alerts/profrac-nasdaqacdc-announces-quarterly-earnings-results-2025-08-08/
[2] https://finance.yahoo.com/quote/ACEL/latest-news/
[3] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U424L:0-pulse-biosciences-inc-reports-results-for-the-quarter-ended-june-30-earnings-summary/